Ivermectin Detection in Serum of Onchocerciasis Patients: Relationship to Adverse Reactions

Njoo, F. L.; Beek, W.M.J.; Keukens, H.J.; Wilgenburg, H. van; Oosting, J.; Stilma, J. S.; Kijlstra, Aize

doi:10.4269/ajtmh.1995.52.94

Cited by 37 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was also investigated whether diminished ivermectin absorption could explain the fact that some severely infected onchocerciasis patients experience relatively few adverse effects following ivermectin treatment, although the occurrence and extent of adverse reactions have been related to infection intensity (17). According to this study, there was no observable relation between the plasma concentration after a single oral dose (150 μg/kg) and the occurrence of adverse reactions.…”

Section: Absorptionmentioning

confidence: 87%

The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review

Canga

Sahagún

Diez

et al. 2008

AAPS J

315

238

View full text Add to dashboard Cite

Section: Absorptionmentioning

confidence: 87%

The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review

Canga

Sahagún

Diez

et al. 2008

AAPS J

315

238

View full text Add to dashboard Cite

“…These effects wane in subsequent administrations [67]. No significant association has been found between ivermectin plasma levels and AE recorded [68]. A recent Cochrane review of ivermectin for river blindness shows that side effects are rarely reported [69].…”

Section: Pk Considerations Regarding Safetymentioning

confidence: 99%

Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety

Chaccour

Hammann

Rabinovich

2017

Malar J

105

View full text Add to dashboard Cite

Ivermectin is an endectocide that has been used broadly in single dose community campaigns for the control of onchocerciasis and lymphatic filariasis for more than 30 years. There is now interest in the potential use of ivermectin regimens to reduce malaria transmission, envisaged as community-wide campaigns tailored to transmission patterns and as complement of the local vector control programme. The development of new ivermectin regimens or other novel endectocides will require integrated development of the drug in the context of traditional entomological tools and endpoints. This document examines the main pharmacokinetic and pharmacodynamic parameters of the medicine and their potential influence on its vector control efficacy and safety at population level. This information could be valuable for trial design and clinical development into regulatory and policy pathways.Electronic supplementary materialThe online version of this article (doi:10.1186/s12936-017-1801-4) contains supplementary material, which is available to authorized users.

show abstract

“…In this context, adverse events (AE) to ivermectin have been usually mild, transient, associated with intensity of microfilarial infection and primarily characterized as mild Mazzoti-type reactions to dying microfilaria [36]. No significant association has been found between ivermectin plasma levels and AE [37]. …”

Section: Introductionmentioning

confidence: 99%

Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination

Chaccour

Kobylinski

Bassat

et al. 2013

Malar J

172

View full text Add to dashboard Cite

BackgroundThe heterogeneity of malaria transmission makes widespread elimination a difficult goal to achieve. Most of the current vector control measures insufficiently target outdoor transmission. Also, insecticide resistance threatens to diminish the efficacy of the most prevalent measures, indoor residual spray and insecticide treated nets. Innovative approaches are needed. The use of endectocides, such as ivermectin, could be an important new addition to the toolbox of anti-malarial measures. Ivermectin effectively targets outdoor transmission, has a novel mechanism of action that could circumvent resistance and might be distributed over the channels already in place for the control of onchocerciasis and lymphatic filariasis.MethodsThe previous works involving ivermectin and Anopheles vectors are reviewed and summarized. A review of ivermectin’s safety profile is also provided. Finally three definitive clinical trials are described in detail and proposed as the evidence needed for implementation. Several smaller and specific supportive studies are also proposed.ConclusionsThe use of ivermectin solves many challenges identified for future vector control strategies. It is an effective and safe endectocide that was approved for human use more than 25 years ago. Recent studies suggest it might become an effective and complementary strategy in malaria elimination and eradication efforts; however, intensive research will be needed to make this a reality.

show abstract

Ivermectin Detection in Serum of Onchocerciasis Patients: Relationship to Adverse Reactions

Cited by 37 publications

References 0 publications

The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review

The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review

Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety

Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination

Contact Info

Product

Resources

About